Table 2 Summary of adverse events
Toxicity | Peptide | Total patients (n = 11) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.5 mg (n = 3) | 1.0 mg (n = 3) | 3.0 mg (n = 5) | ||||||||||
Grade* | Grade | Grade | Grade (%) | |||||||||
1 | 2 | 3 | 1 | 2 | 3 | 1 | 2 | 3 | 1 | 2 | 3 | |
Dermatology/skin | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  Reaction at the injection site | 2 | 0 | 0 | 3 | 0 | 0 | 4 | 0 | 0 | 9 (81.8) | 0 (0.0) | 0 (0.0) |
Hematological | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  Leukocyte | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 1 | 2 | 0 (0.0) | 1 (9.1) | 6 (54.5) |
  Neutrocyte | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 2 | 1 | 0 (0.0) | 4 (36.4) | 3 (27.3) |
  Hemoglobin | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 (27.3) | 3 (27.3) | 3 (27.3) |
  Platelet | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 4 (36.4) | 0 (0.0) | 1 (9.1) |
Non-hematological | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  Esophagitis | 0 | 1 | 0 | 2 | 0 | 0 | 2 | 1 | 0 | 4 (36.4) | 2 (18.2) | 0 (0.0) |
  AST | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 (18.2) | 0 (0.0) | 0 (0.0) |
  ALT | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 (9.1) | 0 (0.0) | 0 (0.0) |
  Creatinine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
  Nausea/vomiting | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 (9.1) | 2 (18.2) | 0 (0.0) |
  Diarrhea | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.0) | 1 (9.1) | 0 (0.0) |
Stomatitis/pharyngitis | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 (0.0) | 3 (27.3) | 0 (0.0) |
  Hyponatremia | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 (18.2) | 3 (27.3) | 0 (0.0) |